MrGuHHH personal page - To The Moon

MrGuHHH

MrGuHHH

No personal profile

6Follow

0Followers

0Topic

0Badge

2021-08-24

$Bumble Inc.(BMBL)$always up and down

2021-08-17

Ok

Tencent Music earnings beat estimates on subscriber, ad boost

2021-08-02

ok

Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet

2021-07-30

$Robinhood Markets, Inc.(HOOD)$short this to death everyone

2021-07-15

Pls like

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585044989004914","uuid":"3585044989004914","gmtCreate":1626318535408,"gmtModify":1626326493816,"name":"MrGuHHH","pinyin":"mrguhhh","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":835446708,"gmtCreate":1629735326104,"gmtModify":1676530117085,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BMBL\">$Bumble Inc.(BMBL)$</a>always up and down","listText":"<a href=\"https://laohu8.com/S/BMBL\">$Bumble Inc.(BMBL)$</a>always up and down","text":"$Bumble Inc.(BMBL)$always up and down","images":[{"img":"https://static.tigerbbs.com/969d10c60fe161d62599448553f4177a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835446708","isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":839439083,"gmtCreate":1629171761442,"gmtModify":1676529953250,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839439083","repostId":"1132782904","repostType":4,"repost":{"id":"1132782904","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629154076,"share":"https://ttm.financial/m/news/1132782904?lang=&edition=fundamental","pubTime":"2021-08-17 06:47","market":"us","language":"en","title":"Tencent Music earnings beat estimates on subscriber, ad boost","url":"https://stock-news.laohu8.com/highlight/detail?id=1132782904","media":"Tiger Newspress","summary":"(Update: August 16, 2021 at 9:41 a.m. ET)\nTencent Music fell over 8% in morning trading Tuesday.\n\nCh","content":"<p><i>(Update: August 16, 2021 at 9:41 a.m. ET)</i></p>\n<p><a href=\"https://laohu8.com/S/TME\">Tencent Music</a> fell&nbsp;over&nbsp;8%&nbsp;in&nbsp;morning&nbsp;trading&nbsp;Tuesday.</p>\n<p><img src=\"https://static.tigerbbs.com/04723d8ee28ade3b89d17c69d5941e40\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p>\n<p>China's Tencent Music Entertainment Group(TME.N)beat Wall Street expectations for second-quarter profit on Monday as its advertising business rebounded and more people subscribed to its music streaming platform.</p>\n<p>Paid subscribers for the company's online music service grew by 41% to 66.2 million, thanks to investments in long-form audio and a refreshed music library expanded by licensing deals with Universal Music Group, Sony Music and other labels.</p>\n<p>Tencent Music shares were up 3.1% in extended trading. They have lost half of their market value this year due to a ruling that barred the company's parent, Tencent Holdings Ltd, from exclusive music copyright agreements.</p>\n<p><img src=\"https://static.tigerbbs.com/f5f85b9406d6ed4f369df89d7ec11fd9\" tg-width=\"899\" tg-height=\"640\" referrerpolicy=\"no-referrer\"></p>\n<p>The company said it expected the decision to have some impact on its operations, without specifying a figure.</p>\n<p>Losing exclusive rights means Tencent Music will likely have to redouble efforts to build a more interactive community while facing a challenge from ByteDance that is using Douyin - the Chinese version of TikTok - to promote music backed by sophisticated algorithms.</p>\n<p>Tencent Music's social entertainment services business, which includes karaoke platforms where users can live stream concerts, posted a 7.4% rise in revenue to 5.06 billion yuan in the quarter and accounted for most of its revenue.</p>\n<p>Total revenue rose by 15.5% to 8.01 billion yuan ($1.24 billion), but missed a Refinitiv IBES estimate of 8.13 billion yuan.</p>\n<p>The company earned 0.66 yuan per American depository share on an adjusted basis, more than estimates of 0.62 yuan.</p>\n<p>($1 = 6.4742 Chinese yuan renminbi)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tencent Music earnings beat estimates on subscriber, ad boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTencent Music earnings beat estimates on subscriber, ad boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-17 06:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><i>(Update: August 16, 2021 at 9:41 a.m. ET)</i></p>\n<p><a href=\"https://laohu8.com/S/TME\">Tencent Music</a> fell&nbsp;over&nbsp;8%&nbsp;in&nbsp;morning&nbsp;trading&nbsp;Tuesday.</p>\n<p><img src=\"https://static.tigerbbs.com/04723d8ee28ade3b89d17c69d5941e40\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\"></p>\n<p>China's Tencent Music Entertainment Group(TME.N)beat Wall Street expectations for second-quarter profit on Monday as its advertising business rebounded and more people subscribed to its music streaming platform.</p>\n<p>Paid subscribers for the company's online music service grew by 41% to 66.2 million, thanks to investments in long-form audio and a refreshed music library expanded by licensing deals with Universal Music Group, Sony Music and other labels.</p>\n<p>Tencent Music shares were up 3.1% in extended trading. They have lost half of their market value this year due to a ruling that barred the company's parent, Tencent Holdings Ltd, from exclusive music copyright agreements.</p>\n<p><img src=\"https://static.tigerbbs.com/f5f85b9406d6ed4f369df89d7ec11fd9\" tg-width=\"899\" tg-height=\"640\" referrerpolicy=\"no-referrer\"></p>\n<p>The company said it expected the decision to have some impact on its operations, without specifying a figure.</p>\n<p>Losing exclusive rights means Tencent Music will likely have to redouble efforts to build a more interactive community while facing a challenge from ByteDance that is using Douyin - the Chinese version of TikTok - to promote music backed by sophisticated algorithms.</p>\n<p>Tencent Music's social entertainment services business, which includes karaoke platforms where users can live stream concerts, posted a 7.4% rise in revenue to 5.06 billion yuan in the quarter and accounted for most of its revenue.</p>\n<p>Total revenue rose by 15.5% to 8.01 billion yuan ($1.24 billion), but missed a Refinitiv IBES estimate of 8.13 billion yuan.</p>\n<p>The company earned 0.66 yuan per American depository share on an adjusted basis, more than estimates of 0.62 yuan.</p>\n<p>($1 = 6.4742 Chinese yuan renminbi)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TME":"腾讯音乐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132782904","content_text":"(Update: August 16, 2021 at 9:41 a.m. ET)\nTencent Music fell over 8% in morning trading Tuesday.\n\nChina's Tencent Music Entertainment Group(TME.N)beat Wall Street expectations for second-quarter profit on Monday as its advertising business rebounded and more people subscribed to its music streaming platform.\nPaid subscribers for the company's online music service grew by 41% to 66.2 million, thanks to investments in long-form audio and a refreshed music library expanded by licensing deals with Universal Music Group, Sony Music and other labels.\nTencent Music shares were up 3.1% in extended trading. They have lost half of their market value this year due to a ruling that barred the company's parent, Tencent Holdings Ltd, from exclusive music copyright agreements.\n\nThe company said it expected the decision to have some impact on its operations, without specifying a figure.\nLosing exclusive rights means Tencent Music will likely have to redouble efforts to build a more interactive community while facing a challenge from ByteDance that is using Douyin - the Chinese version of TikTok - to promote music backed by sophisticated algorithms.\nTencent Music's social entertainment services business, which includes karaoke platforms where users can live stream concerts, posted a 7.4% rise in revenue to 5.06 billion yuan in the quarter and accounted for most of its revenue.\nTotal revenue rose by 15.5% to 8.01 billion yuan ($1.24 billion), but missed a Refinitiv IBES estimate of 8.13 billion yuan.\nThe company earned 0.66 yuan per American depository share on an adjusted basis, more than estimates of 0.62 yuan.\n($1 = 6.4742 Chinese yuan renminbi)","news_type":1},"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804949545,"gmtCreate":1627917948787,"gmtModify":1703497938940,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804949545","repostId":"1164080452","repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806862204,"gmtCreate":1627649918408,"gmtModify":1703494064322,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>short this to death everyone&nbsp;","listText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>short this to death everyone&nbsp;","text":"$Robinhood Markets, Inc.(HOOD)$short this to death everyone","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806862204","isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147514369,"gmtCreate":1626363656551,"gmtModify":1703758812362,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147514369","repostId":"2151251345","repostType":4,"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":804949545,"gmtCreate":1627917948787,"gmtModify":1703497938940,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804949545","repostId":"1164080452","repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839439083,"gmtCreate":1629171761442,"gmtModify":1676529953250,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839439083","repostId":"1132782904","repostType":4,"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806862204,"gmtCreate":1627649918408,"gmtModify":1703494064322,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>short this to death everyone&nbsp;","listText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>short this to death everyone&nbsp;","text":"$Robinhood Markets, Inc.(HOOD)$short this to death everyone","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806862204","isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147514369,"gmtCreate":1626363656551,"gmtModify":1703758812362,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147514369","repostId":"2151251345","repostType":4,"repost":{"id":"2151251345","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626343025,"share":"https://ttm.financial/m/news/2151251345?lang=&edition=fundamental","pubTime":"2021-07-15 17:57","market":"us","language":"en","title":"UnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2151251345","media":"Benzinga","summary":"UnitedHealth Group (NYSE:UNH) reported quarterly earnings of $4.70 per share which beat the analyst consensus estimate of $4.43 by 6.09 percent. This is a 33.99 percent decrease over earnings of $7.12 per share from the","content":"<p>UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.</p>\n<p>The industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.</p>\n<p>For the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.</p>\n<p>Nearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.</p>\n<p>Revenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.</p>\n<p>UnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.</p>\n<p>The company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-15 17:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.</p>\n<p>The industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.</p>\n<p>For the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.</p>\n<p>Nearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.</p>\n<p>Revenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.</p>\n<p>UnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.</p>\n<p>The company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UNH":"联合健康","QTWO":"Q2 Holdings Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151251345","content_text":"UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.\nThe industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.\nFor the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.\nNearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.\nRevenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.\nUnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.\nThe company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.","news_type":1},"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835446708,"gmtCreate":1629735326104,"gmtModify":1676530117085,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BMBL\">$Bumble Inc.(BMBL)$</a>always up and down","listText":"<a href=\"https://laohu8.com/S/BMBL\">$Bumble Inc.(BMBL)$</a>always up and down","text":"$Bumble Inc.(BMBL)$always up and down","images":[{"img":"https://static.tigerbbs.com/969d10c60fe161d62599448553f4177a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835446708","isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}